Polyrizon Ltd. (NASDAQ: PLRZ) signed its first Clinical Trial Agreement with a U.S.-based clinical research site in Texas for its NASARIX™ Allergy Blocker clinical trial, the company announced May 13.

The Texas facility will serve as the first participating center in Polyrizon's planned multi-center study evaluating the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis.

The clinical study will assess the performance of Polyrizon's investigational nasal spray designed to create a protective barrier against airborne allergens. The trial will compare PL-14 Allergy Blocker to saline spray in patients with seasonal allergic rhinitis.

"This agreement represents an important step in transitioning NASARIX™ from development stage into potential clinical validation," said Tomer Izraeli, CEO of Polyrizon.

The study is planned as a multi-center trial, with additional clinical sites expected to be added in the coming months. The trial will be conducted in accordance with international Good Clinical Practice standards and applicable regulatory requirements.

NASARIX™ is an investigational intranasal formulation designed to provide a non-pharmacological barrier against allergens. Polyrizon specializes in developing medical device hydrogels delivered as nasal sprays that form a thin hydrogel-based shield in the nasal cavity.

The Israel-based development-stage biotech company's proprietary Capture and Contain hydrogel technology uses naturally occurring building blocks delivered as nasal sprays. The company is also developing Trap and Target technology focused on nasal delivery of active pharmaceutical ingredients, which is in earlier pre-clinical development stages.